Egetis Therapeutics AB (publ) Total Assets

Latest as of March 2026: Skr537.40 Million SEK ≈ $57.83 Million USD

Egetis Therapeutics AB (publ) total assets. Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) holds total assets worth Skr537.40 Million SEK (≈ $57.83 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Egetis Therapeutics AB (publ) market cap and net worth for the company's overall valuation and market capitalisation.

Total Assets of Egetis Therapeutics AB (publ) (2008–2025)

Total assets of Egetis Therapeutics AB (publ) from 2008 to 2025. This chart illustrates how Egetis Therapeutics AB (publ)'s total assets have evolved over time, based on quarterly financial data. See latest Egetis Therapeutics AB (publ) stock price today for real-time trading data and today's change.

Egetis Therapeutics AB (publ) - Asset Composition Analysis

Egetis Therapeutics AB (publ) Total Assets Breakdown (December 2025)

Egetis Therapeutics AB (publ) total assets breakdown as of December 2025. Egetis Therapeutics AB (publ)'s total assets of Skr537.40 Million consist of 39.7% current assets and 60.3% non-current assets.

Asset Category	Amount (SEK)	% of Total Assets
Cash & Equivalents	Skr0.00	33.8%
Accounts Receivable	Skr27.90 Million	4.4%
Inventory	Skr2.30 Million	0.4%
Property, Plant & Equipment	Skr0.00	0.0%
Intangible Assets	Skr373.30 Million	58.4%
Goodwill	Skr0.00	0.0%

Asset Composition Trend (2008–2025)

This chart illustrates how Egetis Therapeutics AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Egetis Therapeutics AB (publ) (EGTX) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Egetis Therapeutics AB (publ)'s current assets represent 39.7% of total assets in 2025, an increase from 15.3% in 2008.
Cash Position: Cash and equivalents constituted 33.8% of total assets in 2025, up from 13.4% in 2008.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 58.0% of total assets, an increase from 0.0% in 2008.
Asset Diversification: The largest asset category is intangible assets at 58.4% of total assets.

Egetis Therapeutics AB (publ) Competitors by Total Assets

Key competitors of Egetis Therapeutics AB (publ) based on total assets are shown below.

Company	Country	Total Assets
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	USA	$1.26 Billion
Verona Pharma plc F:I9SA	Germany	€572.87 Million
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	USA	$641.76 Million
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	China	CN¥37.46 Billion
Metsera, Inc. Common Stock NASDAQ:MTSR	USA	$639.66 Million
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Bavarian Nordic CO:BAVA	Denmark	Dkr14.95 Billion
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥4.66 Billion

Egetis Therapeutics AB (publ) - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.69	1.53	3.54
Quick Ratio	0.68	1.53	3.51
Cash Ratio	0.00	0.00	0.00
Working Capital	Skr-73.60 Million	Skr106.40 Million	Skr170.53 Million

Egetis Therapeutics AB (publ) - Advanced Valuation Insights

This section examines the relationship between Egetis Therapeutics AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	13.08
Latest Market Cap to Assets Ratio	0.78
Asset Growth Rate (YoY)	-19.3%
Total Assets	Skr639.10 Million
Market Capitalization	$499.86 Million USD

Valuation Analysis

Below Book Valuation: The market values Egetis Therapeutics AB (publ)'s assets below their book value (0.78x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Egetis Therapeutics AB (publ)'s assets decreased by 19.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Egetis Therapeutics AB (publ) (2008–2025)

The table below shows the annual total assets of Egetis Therapeutics AB (publ) from 2008 to 2025.

Year	Total Assets	Change
2025-12-31	Skr639.10 Million ≈ $68.78 Million	-19.34%
2024-12-31	Skr792.30 Million ≈ $85.26 Million	+4.22%
2023-12-31	Skr760.20 Million ≈ $81.81 Million	+35.48%
2022-12-31	Skr561.10 Million ≈ $60.38 Million	-1.43%
2021-12-31	Skr569.27 Million ≈ $61.26 Million	-36.32%
2020-12-31	Skr893.97 Million ≈ $96.21 Million	+231.01%
2019-12-31	Skr270.07 Million ≈ $29.06 Million	+11.58%
2018-12-31	Skr242.04 Million ≈ $26.05 Million	-23.25%
2017-12-31	Skr315.37 Million ≈ $33.94 Million	-20.45%
2016-12-31	Skr396.44 Million ≈ $42.66 Million	+657.12%
2015-12-31	Skr52.36 Million ≈ $5.63 Million	-49.39%
2014-12-31	Skr103.47 Million ≈ $11.13 Million	+102.83%
2013-12-31	Skr51.01 Million ≈ $5.49 Million	-15.62%
2012-12-31	Skr60.46 Million ≈ $6.51 Million	-33.87%
2011-12-31	Skr91.42 Million ≈ $9.84 Million	+976.56%
2010-12-31	Skr8.49 Million ≈ $913.91K	+43.58%
2009-12-31	Skr5.91 Million ≈ $636.49K	+10.12%
2008-12-31	Skr5.37 Million ≈ $578.00K	--

About Egetis Therapeutics AB (publ)

ST:EGTX Sweden Biotechnology

Market Cap

$499.86 Million

Skr4.64 Billion SEK

Market Cap Rank

#11926 Global

#196 in Sweden

Share Price

Skr9.99

Change (1 day)

+0.50%

52-Week Range

Skr4.32 - Skr10.34

All Time High

Skr57.90